View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 4, 2017

Erytech begins Phase II trial of eryaspase to treat ALL

French biopharmaceutical firm Erytech Pharma has begun a Phase II clinical trial of eryaspase (GRASPA) for the treatment of patients with acute lymphoblastic leukaemia (ALL).

French biopharmaceutical firm Erytech Pharma has begun a Phase II clinical trial of eryaspase (GRASPA) for the treatment of patients with acute lymphoblastic leukaemia (ALL).

Eryaspase contains an enzyme called L-asparaginase, encapsulated inside donor-derived red blood cells using the firm's ERYCAPS platform.

The single arm, multi-centre, investigator-initiated, multi-national Phase II trial is designed to evaluate the combination of eryaspase and Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL 2008 multi-agent chemotherapy protocol in 30 subjects.

The trial is to be conducted in partnership with NOPHO and will recruit patients at 23 sites in seven Nordic and Baltic countries, including Denmark, Finland, Norway, Sweden, Iceland, Lithuania and Estonia.

"Eryaspase contains an enzyme called L-asparaginase, encapsulated inside donor-derived red blood cells using the firm's ERYCAPS platform."

Erytech Pharma chief medical officer Dr Iman El-Hariry said: "Collaborating with NOPHO is an exciting opportunity for Erytech to evaluate eryaspase in this specific patient population, with the potential to demonstrate expanded application of our technology to treat blood cancers where drug resistance and hypersensitivity clinical reactions to first-line chemotherapies is common.

"This study aligns with our global strategy to develop the ERYCAPS technology with an increased tolerability and efficacy profile for patients who may respond to L-asparaginase when it is delivered through encapsulated red blood cells."

The combination therapy will be given as a second-intention treatment to children or adult patients with silent inactivation or hypersensitivity reactions to PEG-asparaginase.

Eryaspase is currently under assessment in a Phase IIb trial in Europe for elderly patients with acute myeloid leukaemia (AML) alongside a Phase II trial in metastatic pancreatic cancer patients, and also in a Phase I trial in the US to treat adults with relapsed or refractory ALL.


Image: Micrograph of acute lymphoblastic leukaemia. Photo: courtesy of Osaretin/Wikipedia.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena